Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.
PYC Therapeutics Limited announced an upcoming investor webinar scheduled for October 13, 2025, to discuss recent changes in its board and management team, as well as progress in its four drug development programs. This event reflects the company’s ongoing commitment to transparency and engagement with stakeholders, highlighting its strategic focus on advancing its RNA therapeutic pipeline and strengthening its industry position.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, specifically targeting monogenic diseases, which have a higher likelihood of success in clinical trials.
Average Trading Volume: 883,509
Technical Sentiment Signal: Sell
Current Market Cap: A$577.4M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.